Institut Curie - Site Saint-Cloud
- Address
- 35 Rue Dailly, 92210 Saint-Cloud, France
Analytical, Diagnostic and Therapeutic Techniques and Equipment
The site emphasizes cutting‑edge diagnostic imaging and molecular monitoring to guide cancer treatment decisions.
- ctDNA‑based surveillance for early detection of relapse
- PSMA PET/CT imaging for oligometastatic prostate cancer
- Advanced radiotherapy planning combined with immunotherapy
Institut Curie – Saint‑Cloud leverages these technologies to improve patient stratification across multiple tumor types.
Digestive System Diseases
Research targets malignancies of the gastrointestinal tract, aiming to test novel systemic therapies and improve outcomes.
- Colorectal cancer trials evaluating targeted agents
- Hepatocellular carcinoma studies with combination regimens
- Esophageal carcinoma combined with definitive chemoradiotherapy
The program integrates precision medicine approaches to address the unique biology of digestive system cancers.
Hemic and Lymphatic Diseases
A broad portfolio focuses on blood‑derived cancers, including acute leukemias and diverse lymphoma subtypes.
- Acute myeloid leukemia (AML) investigational therapies
- Chronic lymphocytic leukemia (CLL) and related disorders
- Follicular, marginal zone, and mantle‑cell lymphomas
- Diffuse large B‑cell lymphoma (DLBCL) treatment optimization
- Myelodysplastic syndrome (MDS) and myeloproliferative overlap studies
These efforts aim to enhance response rates and durability of remission for patients with hematologic malignancies.
Male Urogenital Diseases
Clinical investigations address prostate cancer at various stages, seeking to delay progression and improve survival.
- Oligometastatic prostate cancer evaluated with PSMA‑targeted radioligand therapy
- Biochemically recurrent disease after primary treatment
- Advanced prostate cancer combined with androgen‑deprivation therapy
The site’s work reflects a commitment to personalized strategies for men at risk of disease recurrence.
Neoplasms
A major focus is on solid tumors, especially breast, ovarian, and endometrial cancers, testing innovative combinations and endocrine approaches.
- Advanced or metastatic breast cancer, including HER2‑positive and triple‑negative subtypes
- ER‑positive, HER2‑negative disease evaluated with novel endocrine agents
- Ovarian, fallopian tube, and primary peritoneal carcinoma studies
- Endometrial cancer trials exploring maintenance therapies
- Metastatic non‑small cell lung cancer (mNSCLC) comparative immunotherapy research
These trials aim to expand therapeutic options and extend disease‑free intervals for patients with diverse neoplasms.
Pathological Conditions, Signs and Symptoms
Investigations seek to refine biomarkers and early‑detection methods that signal disease activity or treatment response.
- ctDNA monitoring to predict early death risk
- Early detection of triple‑negative breast cancer relapse
- Biomarker‑driven assessment of treatment efficacy
By focusing on these indicators, Institut Curie – Saint‑Cloud aims to intervene sooner and tailor therapies more precisely.
Environment and Public Health
The center incorporates health‑care environment considerations, ensuring trial safety, patient wellbeing, and broader public health impact.
- Safety and tolerability assessments across novel agents
- Evaluation of survivorship care models
- Integration of patient‑reported outcomes in trial design
This holistic approach supports the delivery of high‑quality oncology care within a responsible public‑health framework.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 63 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 60 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
- 1Institut Curie3active
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Institut Curie7trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institut Curie - Site Saint-Cloud
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| "CUPCAKE": Early detection of triple negative breast cancer relapse: a clinical utility trial | Institut Curie | Phase II | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 63 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 6 | Unknown | 2020-01-20 | 2025-09-03 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.